Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy
about
Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.Targeting the cell cycle in breast cancer: towards the next phaseIntroduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N-neopentyl
P2860
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@ast
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@en
type
label
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@ast
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@en
prefLabel
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@ast
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@en
P2093
P2860
P50
P356
P1476
Characterisation of CCT271850, ...... bition vs therapeutic efficacy
@en
P2093
Alexis K De Haven Brandon
Angela Hayes
Cristina P R Xavier
Grace W Y Mak
Isaac M Westwood
Jessica Schmitt
Julian Blagg
Lisa O'Fee
Mark D Gurden
P2860
P2888
P304
P356
10.1038/BJC.2017.75
P407
P577
2017-03-23T00:00:00Z
P6179
1084127758